US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Daiichi Sankyo Co., Ltd.

21.10

-1.6150-7.11%

Volume:278.49K

Turnover:6.39M

Market Cap:40.44B

PE:28.42

High:24.20

Open:20.95

Low:20.95

Close:22.72

Loading ...

Overview Company News Filings

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn

AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC

QuANTUM-Wild Phase 3 Trial of VANFLYTA® Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML

Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer in TROPION-Lung05 and TROPION-Lung01 Pooled Analysis

Daiichi Sankyo Highlights Progress Across Oncology Portfolio in Multiple Solid and Blood Cancers at ESMO Asia, SABCS and ASH

GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study

Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS

AstraZeneca, Daiichi file for FDA accelerated approval of Dato-DXd

Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology

ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product

Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DSKYF/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DSKYF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DSKYF\",,,,,undefined,":{"symbol":"DSKYF","market":"US","secType":"STK","nameCN":"Daiichi Sankyo Co., Ltd.","latestPrice":21.1,"timestamp":1744315200000,"preClose":22.715,"halted":0,"volume":278493,"delay":15,"floatShares":1876450459,"shares":1916602000,"eps":0.742527,"marketStatus":"Closed","change":-1.615,"latestTime":"04-10 16:00:00 EDT Delay","open":20.95,"high":24.2,"low":20.95,"amount":6393851.085,"amplitude":0.143077,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.742527,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1744358400000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":22.715,"volumeRatio":12.855936},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DSKYF\",,,,,undefined,":{"symbol":"DSKYF","floatShares":1876450459,"roa":"4.94%","roe":"15.29%","lyrEps":0.692127,"volumeRatio":12.855936,"shares":1916602000,"dividePrice":0.41916,"high":24.2,"amplitude":0.143077,"preClose":22.715,"low":20.95,"week52Low":20.24,"pbRate":"3.56","psRate":"3.22","week52High":44.64,"institutionHeld":0,"latestPrice":21.1,"eps":0.742527,"divideRate":0.019865,"volume":278493,"delay":15,"ttmEps":0.742527,"open":20.95,"prevYearClose":26.6,"prevWeekClose":23.625,"prevMonthClose":22.01,"prevQuarterClose":22.01,"fiveDayClose":22.8,"twentyDayClose":23.54,"sixtyDayClose":24.92},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DSKYF\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2493775992","title":"Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn","url":"https://stock-news.laohu8.com/highlight/detail?id=2493775992","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493775992?lang=en_us&edition=fundamental","pubTime":"2024-12-24 15:00","pubTimestamp":1735023600,"startTime":"0","endTime":"0","summary":"TOKYO & MUNICH, December 24, 2024----Daiichi Sankyo  and AstraZeneca  have voluntarily withdrawn the marketing authorization application  in the EU for datopotamab deruxtecan  for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer  based on the TROPION-Lung01 phase 3 trial.The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency . Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings.Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate  discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and AstraZeneca.A","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sv.qf7zkcH93Ibh2s9cInQ--~B/aD00NzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e6e065d92bcbe7bb3f01287baca7ae27","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sv.qf7zkcH93Ibh2s9cInQ--~B/aD00NzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e6e065d92bcbe7bb3f01287baca7ae27"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/datopotamab-deruxtecan-application-eu-patients-070000830.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4080","BK4156","IE00B66KJ199.SGD","ADC","BK4225","BK4097","HR","BK4585","PFS","MAA","IE00B19Z4B17.USD","BK4215","BK4588","DSKYF","AEIS","PBD","OS","IE00B7SZL793.SGD","BK4211","DSNKY","BK4203","BK4007","IE0031619046.USD","BK4231","BK4195","BK4157"],"gpt_icon":0},{"id":"2490048967","title":"AZN, Daiichi's ADC Gets FDA Breakthrough Tag for EGFR-Mutated NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2490048967","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490048967?lang=en_us&edition=fundamental","pubTime":"2024-12-10 22:44","pubTimestamp":1733841840,"startTime":"0","endTime":"0","summary":"AstraZeneca AZN and its Japanese partner Daiichi Sankyo announced that the FDA has granted a Breakthrough Therapy designation  to their antibody-drug conjugate , datopotamab deruxtecan , for a lung cancer indication.The regulatory granted the BTD to Dato-DXd for the treatment of locally advanced or metastatic epidermal growth factor receptor-mutated  non-small cell lung cancer  in adult patients whose disease progressed on or after treatment with an EGFR-tyrosine kinase inhibitor  and platinum-based chemotherapy.The FDA’s BTD for Dato-DXd was based on data from the phase II TROPION-Lung05 study and supported by data from the phase III TROPION-Lung01 study.Based on the same data, last month, AstraZeneca and Daiichi Sankyo submitted a new biologics license application  seeking accelerated approval of Dato-DXd for previously treated advanced EGFR-mutated NSCLC.Daiichi Sankyo has six ADCs in clinical development across multiple types of cancers, being developed utilizing its DXd ADC techno","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6pmiwRZRhtc7hxDNA3zxVQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ef77d5a5eb4e72e4dd31ccfaf4ca4ccd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6pmiwRZRhtc7hxDNA3zxVQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ef77d5a5eb4e72e4dd31ccfaf4ca4ccd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/azn-daiichis-adc-gets-fda-144400961.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0122379950.USD","DSNKY","LU1829250122.USD","LU0070302665.USD","LU0889565916.HKD","ADC","LU2361045086.USD","IE00BLSP4452.SGD","LU1093756168.USD","LU1989771016.USD","LU0170899867.USD","LU0985481810.HKD","LU0965509010.AUD","IE00BJT1NW94.SGD","LU0265550946.USD","LU0211331839.USD","LU1061106388.HKD","LU0456855351.SGD","LU1974910355.USD","LU1934455277.USD","LU2023250504.SGD","DSKYF","SG9999014575.USD","LU2236285917.USD","BK4559","AZN","SG9999015358.SGD","LU0208291251.USD","SG9999001440.SGD","IE00B1BXHZ80.USD","IE00BN8TJ469.HKD","BK4516","LU1941712348.USD","LU0225284248.USD","SG9999001176.SGD","IE00BSNM7G36.USD","LU0058720904.USD","LU1894683348.USD","PFE","LU0306807586.USD","LU2324357040.USD","LU0238689110.USD","BK4007","LU0321505868.SGD","LU1037948897.HKD","MRK","SG9999014542.SGD","LU2468319806.SGD","LU2462157665.USD","LU0006306889.USD","LU0289739699.SGD","BK4080"],"gpt_icon":1},{"id":"2490013035","title":"QuANTUM-Wild Phase 3 Trial of VANFLYTA® Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2490013035","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490013035?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:00","pubTimestamp":1733835600,"startTime":"0","endTime":"0","summary":"TOKYO & BASKING RIDGE, N.J., December 10, 2024----The first patient has been dosed in the QuANTUM-Wild phase 3 trial evaluating Daiichi Sankyo’s  VANFLYTA  in combination with standard intensive induction and consolidation chemotherapy followed by single-agent maintenance in adults with newly diagnosed FLT3-ITD negative acute myeloid leukemia .AML is an aggressive blood cancer with a five-year overall survival rate of approximately 32%.1, 2 Targeted therapy with FLT3 inhibitors has improved survival for some patients with FLT3 gene mutations, which most commonly occur as FLT3-ITD.3 However, about 90% of patients with AML overexpress FLT3 regardless of mutational status.1, 4, 5 No FLT3 inhibitors are currently approved for patients without FLT3 mutations.The QuANTUM-Wild trial was initiated based on results of the QUIWI phase 2 trial evaluating VANFLYTA in combination with standard intensive chemotherapy and as subsequent maintenance monotherapy in adult patients with newly diagnosed FL","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LZ.q9Iuft1A.dXEKC2_ciw--~B/aD00NzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c5c6b94e76f92e00dc7e43bf597d2784","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LZ.q9Iuft1A.dXEKC2_ciw--~B/aD00NzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c5c6b94e76f92e00dc7e43bf597d2784"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/quantum-wild-phase-3-trial-130000556.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","DSKYF","DSNKY","CR","BK4161","HSCT"],"gpt_icon":0},{"id":"2490461719","title":"Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2490461719","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490461719?lang=en_us&edition=fundamental","pubTime":"2024-12-09 15:00","pubTimestamp":1733727600,"startTime":"0","endTime":"0","summary":"First Breakthrough Therapy Designation for Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan based on TROPION-Lung05 phase 2 trial and supported by data from TROPION-Lung01 phase 3 trial. Twelfth Breakthrough Therapy Designation granted by FDA across Daiichi Sankyo’s oncology pipeline. TOKYO & BASKING RIDGE, N.J., December 09, 2024----Datopotamab deruxtecan  has been granted Breakthrough Therapy Designation  in the U.S. for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated  non-small cell lung cancer  with disease progression on or after treatment with an EGFR tyrosine kinase inhibitor  and platinum-based chemotherapy.Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate  discovered by Daiichi Sankyo  and being jointly developed by Daiichi Sankyo and AstraZeneca .The U.S. Food and Drug Administration  BTD is designed to accelerate the development and regulatory review of potential ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/od6K9JktxscOtlbnecuwSw--~B/aD00NzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/6c0fc7282dc8dbbaad8d32e58ef66ea8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/od6K9JktxscOtlbnecuwSw--~B/aD00NzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/6c0fc7282dc8dbbaad8d32e58ef66ea8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/datopotamab-deruxtecan-granted-breakthrough-therapy-070000835.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4195","BK4211","IE0031619046.USD","BK4080","PBD","PFS","DSKYF","BK4157","BK4231","BK4097","IE00B19Z4B17.USD","DSNKY","AEIS","BK4007","IE00B66KJ199.SGD","ADC","OS","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2489242393","title":"Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer in TROPION-Lung05 and TROPION-Lung01 Pooled Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2489242393","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489242393?lang=en_us&edition=fundamental","pubTime":"2024-12-06 10:15","pubTimestamp":1733451300,"startTime":"0","endTime":"0","summary":"Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan showed a 42.7% objective response rate in previously treated patients. Data support recent BLA submission in the U.S. for this patient population. TOKYO & BASKING RIDGE, N.J., December 06, 2024----A pooled analysis of the TROPION-Lung05 phase 2 and the TROPION-Lung01 phase 3 trials showed datopotamab deruxtecan  demonstrated clinically meaningful tumor response in patients with previously treated advanced or metastatic EGFR-mutated non-small cell lung cancer . These data, along with progression-free and overall survival results from the analysis, were presented during a late-breaking proffered paper session  at the 2024 ESMO Asia  Congress.Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate  discovered by Daiichi Sankyo  and being jointly developed by Daiichi Sankyo and AstraZeneca .The safety profile of datopotamab deruxtecan was consistent with previous reports from the TROPION-Lung05 a","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FFFV0HSQ0rhQXmzy7suhMQ--~B/aD00NzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/fca47f2662fc4f675cc4545678bdaa58","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FFFV0HSQ0rhQXmzy7suhMQ--~B/aD00NzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/fca47f2662fc4f675cc4545678bdaa58"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/datopotamab-deruxtecan-demonstrated-meaningful-clinical-021500818.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AEIS","DSNKY","OS","AESI","BK4097","DSKYF","IE0031619046.USD","BK4195","IE00B66KJ199.SGD","PFS","BK4211","IE00B7SZL793.SGD","BK4213","SD","BK4007","PBD","IE00B19Z4B17.USD","BK4231","ADC","BK4080","BK4157","BK4179"],"gpt_icon":0},{"id":"2488957110","title":"Daiichi Sankyo Highlights Progress Across Oncology Portfolio in Multiple Solid and Blood Cancers at ESMO Asia, SABCS and ASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2488957110","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488957110?lang=en_us&edition=fundamental","pubTime":"2024-12-02 21:00","pubTimestamp":1733144400,"startTime":"0","endTime":"0","summary":"Three late-breaking presentations across lung and breast cancer trials of three DXd ADCs to be showcased. Science & Technology Day to provide overview of data and strategy across Daiichi Sankyo R&D pipeline. BASKING RIDGE, N.J., December 02, 2024----Daiichi Sankyo  will present new clinical research across its oncology portfolio with more than 45 abstracts in multiple types of solid and blood cancers at the 2024 ESMO Asia Congress , San Antonio Breast Cancer Symposium  and American Society of Hematology  Annual Meeting prior to its Science & Technology Day.\"Important updates in difficult-to-treat cancers including lung, breast, gastric and biliary tract cancer as well as acute myeloid leukemia and peripheral T-cell lymphoma will be highlighted at these upcoming meetings,\" said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. \"We continue to make important progress with our approved and pipeline medicines with the goal of changing the standard of care across a wide range of cancers.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cY88dbmI1XxsMFQZFBouAA--~B/aD00NzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/833a7ce6e6a3c8b494d8cbffdb4e6c79","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cY88dbmI1XxsMFQZFBouAA--~B/aD00NzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/833a7ce6e6a3c8b494d8cbffdb4e6c79"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/daiichi-sankyo-highlights-progress-across-130000400.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2463526074.USD","PST","DSKYF","DSNKY","PRGS","CST","LU2065732104.USD","BK4109","IHC","BK4097","BK4007","BK4162","PBD","ASH"],"gpt_icon":0},{"id":"2484798955","title":"GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2484798955","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484798955?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:01","pubTimestamp":1731963660,"startTime":"0","endTime":"0","summary":"MENLO PARK, Calif., Nov. 18, 2024 /PRNewswire/ -- GRAIL, Inc. , a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient has been tested for eligibilitywith the investigational GRAIL Non-Small Cell Lung Cancer  ctDNA Assay in the global TROPION-Lung12 Phase 3 study evaluating adjuvant treatment regimens in patients with Stage I adenocarcinoma NSCLC. The study is sponsored by AstraZeneca  in collaboration with Daiichi Sankyo .In 2022, GRAIL announced a broad strategic collaboration with AstraZeneca to develop and commercialize companion diagnostic  assays for use with AstraZeneca's therapies. GRAIL is committed to leveraging its blood-based methylation testing for patient care by developing fit-for-purpose diagnostics to enable precision oncology strategies with biopharma partne","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H0W_YR0aAlLQ9_M4J5MNSg--~B/aD03Njt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/df6f1c041e7249704f56bfd0aaad45cf","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H0W_YR0aAlLQ9_M4J5MNSg--~B/aD03Njt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/df6f1c041e7249704f56bfd0aaad45cf"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/grail-announces-first-patient-tested-210100573.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/grail-announces-first-patient-tested-210100573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","DSKYF","AZN","CLIA","DSNKY","GRAL"],"gpt_icon":0},{"id":"2483755002","title":"Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS","url":"https://stock-news.laohu8.com/highlight/detail?id=2483755002","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483755002?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:00","pubTimestamp":1731502800,"startTime":"0","endTime":"0","summary":"BASKING RIDGE, N.J., November 13, 2024----Daiichi Sankyo  will highlight new clinical research and real-world data from seven abstracts for TURALIO  at the Connective Tissue Oncology Society  2024 Annual Meeting.TURALIO is the first and only oral systemic therapy approved in the U.S. for adult patients with tenosynovial giant cell tumor  associated with severe morbidity or functional limitations and not amenable to improvement with surgery. TGCT is a rare and typically non-malignant tumor that affects small and large joints.1,2,3. \"These latest data being presented at CTOS continue to support the role of TURALIO as a treatment option for certain patients with tenosynovial giant cell tumor,\" said Dan Switzer, Head of U.S. Oncology Business, Daiichi Sankyo, Inc. \"As a leader in TGCT research and development, Daiichi Sankyo has made significant progress in transforming the treatment landscape for patients with this rare, debilitating tumor and we remain committed to educating the medical ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Q_Ud.j.faz9TGQm1x1aHQg--~B/aD0yODA7dz0yNjc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/0eaf3e57716fb77929dd27bf6662f931","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Q_Ud.j.faz9TGQm1x1aHQg--~B/aD0yODA7dz0yNjc7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/0eaf3e57716fb77929dd27bf6662f931"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/daiichi-sankyo-showcase-turalio-research-130000028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALT","PST","DSNKY","CTOS","BK4139","BK4007","BK4104","AST","LU1878469433.USD","DSKYF","GGT"],"gpt_icon":0},{"id":"2483030382","title":"AstraZeneca, Daiichi file for FDA accelerated approval of Dato-DXd","url":"https://stock-news.laohu8.com/highlight/detail?id=2483030382","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483030382?lang=en_us&edition=fundamental","pubTime":"2024-11-13 02:28","pubTimestamp":1731436117,"startTime":"0","endTime":"0","summary":"Roland Magnusson  AstraZeneca  and Daiichi Sankyo   have withdrawn their FDA application for datopotamab deruxtecan, or Dato-DXd, for the treatment of nonsquamous non-small cell lung cancer, or NSCLC, and instead have filed for accelerated approval of the product for","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1250576655/image_1250576655.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1250576655/image_1250576655.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4281534-astrazeneca-daiichi-file-for-fda-accelerated-approval-of-dato-dxd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["QID","PSQ","DSKYF","TQQQ","LU2417539215.USD","LU2456880835.USD",".IXIC","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","LU1829250122.USD","BK4585","BK4007","BK4588","DSNKY","QLD","AZN","MNQmain","BK4568","LU2236285917.USD","LU2462157665.USD","NQmain","SQQQ"],"gpt_icon":0},{"id":"2482740083","title":"Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2482740083","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482740083?lang=en_us&edition=fundamental","pubTime":"2024-11-12 15:00","pubTimestamp":1731394800,"startTime":"0","endTime":"0","summary":"Daiichi Sankyo and AstraZeneca’s new application is based on the TROPION-Lung05 phase 2 trial and supported by data from additional trials including TROPION-Lung01. Previously submitted BLA based on TROPION-Lung01 phase 3 trial for patients with nonsquamous NSCLC has been voluntarily withdrawn. TOKYO & BASKING RIDGE, N.J., November 12, 2024----Daiichi Sankyo  and AstraZeneca  have submitted a new Biologics License Application  for accelerated approval in the U.S. for datopotamab deruxtecan  for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated  non-small cell lung cancer  who have received prior systemic therapies, including an EGFR-directed therapy.Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate  discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and AstraZeneca.\"Treating EGFR-mutated non-small cell lung cancer is incredibly challenging following disease pr","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/PQtImeMlNxA2wqoBrgTffg--~B/aD01MDA7dz0yMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/867d413bf16e2a4954b2377671109f13","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/PQtImeMlNxA2wqoBrgTffg--~B/aD01MDA7dz0yMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/867d413bf16e2a4954b2377671109f13"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/datopotamab-deruxtecan-bla-submitted-accelerated-070000417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PFS","BK4080","IE00B66KJ199.SGD","BK4097","ADC","BK4211","BK4195","BK4157","BK4231","DSNKY","OS","IE00B7SZL793.SGD","IE00B19Z4B17.USD","IE0031619046.USD","BK4007","AEIS","PBD","DSKYF"],"gpt_icon":0},{"id":"2482192972","title":"Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2482192972","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482192972?lang=en_us&edition=fundamental","pubTime":"2024-11-11 08:07","pubTimestamp":1731283620,"startTime":"0","endTime":"0","summary":"Alteogen will receive an upfront payment and is eligible to receive milestone payments upon Daiichi Sankyo's achievement of specified development, regulatory and sales milestones. Additionally, Alteogen will be entitled to receive tiered royalties on the sales of the commercialized product. Alteogen will be responsible for clinical and commercial supply of ALT-B4 to Daiichi Sankyo.\"Our collaboration with Daiichi Sankyo is groundbreaking in the ADC field, being the first to use hyaluronidase for a subcutaneous ADC marks a significant milestone in the oncology field, and we look forward to our collaboration with Daiichi Sankyo in bringing this product to the market.\" said Dr. Soon Jae Park, Chief Executive Officer of Alteogen.ALT-B4 is Alteogen's proprietary human recombinant hyaluronidase enzyme developed utilizing Hybrozyme technology. ALT-B4 can enable the large volume subcutaneous administration of drugs that are typically administered as an IV infusion. ALT-B4 does this by temporari","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/h1ksztEd.ZDxxV9avnASTA--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/b480751217257d96cbf09949813ff1e2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/h1ksztEd.ZDxxV9avnASTA--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/b480751217257d96cbf09949813ff1e2"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/alteogen-enters-exclusive-license-agreement-000700768.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alteogen-enters-exclusive-license-agreement-000700768.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["DSKYF","BK4080","DSNKY","BK4007","ADC","BK4231"],"gpt_icon":0},{"id":"2481177964","title":"ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product","url":"https://stock-news.laohu8.com/highlight/detail?id=2481177964","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481177964?lang=en_us&edition=fundamental","pubTime":"2024-11-08 21:00","pubTimestamp":1731070800,"startTime":"0","endTime":"0","summary":"TOKYO & BASKING RIDGE, N.J., November 08, 2024----Daiichi Sankyo  and AstraZeneca  have been awarded The Galien Foundation 2024 Prix Galien USA Award for Best Biotechnology Product for ENHERTU .ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate  discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca.About ENHERTU ENHERTU  is a HER2 directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, ENHERTU is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced program in AstraZeneca’s ADC scientific platform. ENHERTU consists of a HER2 monoclonal antibody attached to a number of topoisomerase I inhibitor payloads  via tetrapeptide-based cleavable linkers.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/cGP_01llzXYL4xmrsUlObg--~B/aD00NzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/bda0c71d860359e577df57a5ff9030ef","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/cGP_01llzXYL4xmrsUlObg--~B/aD00NzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/bda0c71d860359e577df57a5ff9030ef"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/enhertu-receives-prestigious-2024-prix-130000957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4231","PBD","DSNKY","DSKYF","BK4007","BK4080","ADC"],"gpt_icon":0},{"id":"2479202869","title":"Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2479202869","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479202869?lang=en_us&edition=fundamental","pubTime":"2024-10-30 20:00","pubTimestamp":1730289600,"startTime":"0","endTime":"0","summary":"TROPION-Lung10 is evaluating Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus rilvegostomig as first-line treatment for advanced or metastatic nonsquamous NSCLC with high PD-L1 expression without actionable genomic alterations. TROPION-Lung14 is evaluating datopotamab deruxtecan plus osimertinib as first-line treatment for advanced or metastatic EGFR mutated nonsquamous NSCLC. TROPION-Lung15 is evaluating datopotamab deruxtecan with or without osimertinib for advanced or metastatic EGFR mutated nonsquamous NSCLC that progressed on prior osimertinib. TROPION-Lung14 is evaluating datopotamab deruxtecan plus osimertinib, AstraZeneca’s EGFR tyrosine kinase inhibitor , versus osimertinib alone in patients with previously untreated locally advanced or metastatic EGFR mutated nonsquamous NSCLC.\"Clinical research suggests that combining an antibody drug conjugate with a targeted treatment or a bispecific immunotherapy may drive stronger and more durable tumor responses in patients ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FVcX24_TrbnwSm3d5AwUbg--~B/aD00NzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/b04169c1cd204929015f2bf8c14b2d85","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FVcX24_TrbnwSm3d5AwUbg--~B/aD00NzQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/b04169c1cd204929015f2bf8c14b2d85"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/three-phase-3-trials-datopotamab-120000719.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","LU0053671581.USD","DSKYF","ITT","BK4195","CNS","AEIS","BK4080","ADC","BK4157","IE0031619046.USD","IE00B19Z4B17.USD","IE00B7SZL793.SGD","BK4007","LU0054578231.USD","PFS","BK4231","OS","BK4161","PBD","IE00B66KJ199.SGD","BK4097","DSNKY","BK4135"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":33,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DSKYF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-04-25","symbol":"DSKYF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1714017600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-01-30","symbol":"DSKYF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1706590800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-11-07","symbol":"DSKYF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1699333200000,"reportTimeType":"post","actualEps":null},{"date":"2023-09-28","symbol":"DSKYF","amount":17,"announcedDate":"2023-07-19","type":"dividend","market":"US","newRecordDate":"2023-09-30","defaultRemindTime":1695907800000,"name":"Daiichi Sankyo Co., Ltd.","recordDate":"2023-12-01","payableDate":"2023-09-30","currency":"JPY","dateTimestamp":1695873600000,"payDate":"2023-12-01"},{"market":"US","date":"2023-07-31","symbol":"DSKYF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1690776000000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DSKYF\",market:\"US\",,,undefined,":[{"executeDate":"2019-03-27","recordDate":"2019-03-31","paymentDate":"2019-06-19","value":35,"currency":"JPY"},{"executeDate":"2019-09-27","recordDate":"2019-09-30","paymentDate":"2019-12-03","value":35,"currency":"JPY"},{"executeDate":"2020-03-30","recordDate":"2020-03-31","paymentDate":"2020-06-18","value":35,"currency":"JPY"},{"executeDate":"2020-09-29","recordDate":"2020-09-30","paymentDate":"2020-12-01","value":40.5,"currency":"JPY"},{"executeDate":"2021-03-30","recordDate":"2021-03-31","paymentDate":"2021-06-16","value":13.5,"currency":"JPY"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DSKYF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":2,"updateTime":1721188800000}}}